374
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Prospects for Developmental Immunotoxicity Guidance and an Update on ICH S8

Pages 217-220 | Received 28 Jun 2005, Accepted 29 Sep 2005, Published online: 09 Oct 2008

REFERENCES

  • Barnett J. Developmental immunotoxicology. Experimental Immunotoxicology, R. J. Smialowicz, M. P. Holsapple. CRC Press, Boca Raton, FL 1996; 47–62
  • Dietert R. R. Developmental immunotoxicology: Overview of issues including critical windows of development. Reprod. Toxicol. 2003; 17: 478–479, [CSA]
  • Greely G. H., Kizer J. S. The effects of chronic methylphenidate treatment on growth and endocrine function in the developing rat. J. Pharmacol. Exp. Ther. 1980; 215: 545–551, [CSA]
  • Holsapple M. P., Burns-Naas L. A., Hastings K. L., Ladics G. S., Lavin A. L., Makris S. L., Yang Y., Luster M. I. A proposed testing framework for developmental immunotoxicology (DIT). Toxicol. Sci. 2005; 83: 18–24, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
  • Ladics G. S., Chapin R. E., Hastings K. L., Holsapple M. P., Makris S. L., Sheets L. P., Woolhiser M. R., Burns-Naas L. A. Developmental toxicology evaluations—Issues with including neurotoxicity and immunotoxicology assessments in reproductive toxicology studies. Toxicol. Sci. 2005; 88: 24–29, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
  • Pizzi W. J., Rode E. C., Barnhart J. E. Differential effects of methylphenidate on the growth of neonatal and adolescent rats. Neurotoxicol. Teratol. 1987; 9: 107–111, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
  • Rice D., Barone S., Jr. Critical periods of vulnerability for the developing nervous system: Evidence from humans and animal models. Environ. Health Perspect. 2000; 108(Suppl. 3)511–533, [PUBMED], [INFOTRIEVE], [CSA]
  • The 1998 Pediatric Rule. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients; Final Rule. Fed. Reg., 63: 66632–66672, [CSA]
  • U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry on Immunotoxicology Evaluation of Investigational New Drugs. U.S. FDA, Washington, D.C. 2002
  • Weaver J. L., Tsutsui N., Hisada S., Vidal J. M., Spanhaak S., Sawada J., Hastings K. L., Van der Laan J. W., van Loveren H., Kawabata T. T., Sims J., Durham S. K., Fueki O., Matula T. I., Kusunoki H., Ulrich P., Nakamura K. Meeting Report: Development of the ICH guidelines for immunotoxicology evaluation of pharmaceuticals using a survey of industry practices. J. Immunotoxicol. 2005; 2: 171–180, [CSA], [CROSSREF]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.